News | June 01, 2026
Indoco's formulation plant at Baddi receives EU GMP certification
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
